Research programme: galectin antagonists - UnibioscreenAlternative Names: UNBS 1070; UNBS 3976
Latest Information Update: 16 Jul 2016
At a glance
- Originator Unibioscreen
- Mechanism of Action Galectin inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- Available For Licensing Yes
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for research development in Cancer in Belgium
- 14 Sep 2007 Early research in Cancer in Belgium (unspecified route)
- 14 Sep 2007 The UNBS 1070 programme is available for licensing as of 14 Sep 2007. http://www.unibioscreen.com